inzomelid (IZD174) / Roche - LARVOL DELTA

PET-MRI biomarkers reveal efficacy of a novel NLRP3 inhibitor in Parkinson's disease models. (PubMed, Brain) - "Notably, MCC7840 was effective in a slowly progressing 12-month α-synuclein model, even when administered after symptom onset, 4 months post-α-synuclein injection. These findings highlight the utility of PET/MRI as a non-invasive tool to evaluate drug efficacy and support MCC7840, and other brain-penetrant NLRP3 inhibitors, as promising disease-modifying therapies for Parkinson's disease, warranting future clinical investigation."

Biomarker • Journal • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • NLRP3

"Inflammasome inhibitors in development: - RRx-001 in cancer, ALS, parkinsons - OLT1177 in OA knee, gout, Schnitzlers - DFV890 in CAPs, knee OA - IZD174/334 in CAPS - ZYIL1 CAPS https://t.co/7E2jdx9TPA" (@RheumNow)

CNS Disorders • Gout • Inflammatory Arthritis • Movement Disorders • Oncology • Parkinson's Disease • Rheumatology

PK Study in Patients With Parkinson's Disease With IZD174 (clinicaltrials.gov) - P1b; N=0; Withdrawn; Sponsor: Inflazome UK Ltd; Not yet recruiting ➔ Withdrawn

Clinical • Trial withdrawal • CNS Disorders • Movement Disorders • Parkinson's Disease • IL1B

PK Study in Patients With Parkinson's Disease With IZD174 (clinicaltrials.gov) - P1b; N=6; Not yet recruiting; Sponsor: Inflazome UK Ltd; Initiation date: Jul 2020 ➔ Oct 2020

Clinical • Trial initiation date • CNS Disorders • Movement Disorders • Parkinson's Disease • IL1B

Swiss drug giant Roche pays €380m for Irish biotech Inflazome (The Irish Times) - "Swiss drug giant Roche has paid €380 million upfront for a four-year-old Irish biotech company working on treatments to meet clinically unmet needs in a wide range of debilitating inflammatory diseases. These range from Alzheimer’s and Parkinson’s...The deal gives Roche total control of the Irish business and its research. Inflazome currently has two drugs in clinical trials: Inzomelid, for neurodegenerative diseases in the brain; and Somalix, for inflammatory diseases in the rest of the body."

M&A • CNS Disorders • Parkinson's Disease

PK Study in Patients With Parkinson's Disease With IZD174 (clinicaltrials.gov) - P1b; N=6; Not yet recruiting; Sponsor: Inflazome UK Ltd; Trial completion date: Jun 2020 ➔ Sep 2020; Trial primary completion date: Jun 2020 ➔ Sep 2020

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Gene Therapies • Movement Disorders • Parkinson's Disease • IL1B

PK Study in Patients With Parkinson's Disease With IZD174 (clinicaltrials.gov) - P1b; N=6; Not yet recruiting; Sponsor: Inflazome UK Ltd

Clinical • New P1 trial • IL1B

Safety and Tolerability, Pharmacokinetic and Pharmacodynamic Study With Inzomelid (clinicaltrials.gov) - P1; N=80; Completed; Sponsor: Inflazome UK Ltd; Recruiting ➔ Completed

Trial completion